DE60034586D1 - April rezeptor (bcma) und verwendungen davon - Google Patents

April rezeptor (bcma) und verwendungen davon

Info

Publication number: DE60034586D1
Authority: DE; Germany
Prior art keywords: bcma; april receptor; april; receptor; antibodies
Prior art date: 1999-10-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60034586T

Other languages

English (en)

Other versions

DE60034586T2 (de

Inventor

Pascal Schneider

Jeffrey Thompson

Teresa Cachero

Christine Ambrose

Paul Rennert

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Apotech R & D SA

Biogen Inc

Biogen MA Inc

Original Assignee

Apotech R & D SA

Biogen Idec Inc

Biogen Idec MA Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-06

Filing date

2000-10-05

Publication date

2007-06-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27388102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60034586(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-10-05 Application filed by Apotech R & D SA, Biogen Idec Inc, Biogen Idec MA Inc filed Critical Apotech R & D SA

2007-06-06 Application granted granted Critical

2007-06-06 Publication of DE60034586D1 publication Critical patent/DE60034586D1/de

2008-02-28 Publication of DE60034586T2 publication Critical patent/DE60034586T2/de

2020-10-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DE60034586T 1999-10-06 2000-10-05 April rezeptor (bcma) und verwendungen davon Expired - Lifetime DE60034586T2 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US15793399P	1999-10-06	1999-10-06
US157933P		1999-10-06
US18180700P	2000-02-11	2000-02-11
US181807P		2000-02-11
US21568800P	2000-06-30	2000-06-30
US215688P		2000-06-30
PCT/US2000/027579 WO2001024811A1 (en)	1999-10-06	2000-10-05	April receptor (bcma) and uses thereof

Publications (2)

Publication Number	Publication Date
DE60034586D1 true DE60034586D1 (de)	2007-06-06
DE60034586T2 DE60034586T2 (de)	2008-02-28

Family

ID=27388102

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60034586T Expired - Lifetime DE60034586T2 (de)	1999-10-06	2000-10-05	April rezeptor (bcma) und verwendungen davon

Country Status (30)

Country	Link
US (1)	US7276241B2 (de)
EP (3)	EP1847273A1 (de)
JP (2)	JP4880155B2 (de)
KR (1)	KR100759295B1 (de)
CN (1)	CN1263507C (de)
AT (1)	ATE360434T1 (de)
AU (1)	AU776852B2 (de)
BG (1)	BG65473B1 (de)
BR (1)	BR0014583A (de)
CA (1)	CA2386463C (de)
CZ (1)	CZ297633B6 (de)
DE (1)	DE60034586T2 (de)
DK (1)	DK1223964T3 (de)
EA (1)	EA005601B1 (de)
EE (1)	EE05212B1 (de)
GE (1)	GEP20043375B (de)
HK (1)	HK1044710B (de)
HU (1)	HUP0203567A2 (de)
IL (3)	IL148839A0 (de)
IS (1)	IS6322A (de)
MX (1)	MXPA02003393A (de)
NO (1)	NO331683B1 (de)
NZ (1)	NZ517907A (de)
PL (1)	PL204010B1 (de)
RS (1)	RS51602B (de)
SK (1)	SK286331B6 (de)
TR (1)	TR200200912T2 (de)
UA (1)	UA74798C2 (de)
WO (1)	WO2001024811A1 (de)
ZA (1)	ZA200202578B (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7217788B2 (en)	1996-03-14	2007-05-15	Human Genome Sciences, Inc.	Human tumor necrosis factor delta polypeptides
US6541224B2 (en)	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
ES2629442T3 (es)	1998-06-01	2017-08-09	Agensys, Inc.	Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
GB9828628D0 (en)	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20050100548A1 (en) *	2001-07-24	2005-05-12	Biogen Idec Ma Inc.	BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en)	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2001012812A2 (en)	1999-08-17	2001-02-22	Biogen, Inc.	Baff receptor (bcma), an immunoregulatory agent
AU2048501A (en) *	2000-02-16	2001-08-27	Genentech Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040002068A1 (en) *	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en)	2000-05-04	2008-05-13	Human Genome Sciences, Inc.	Treatment of Sjogren's syndrome by administration of TR18 polypeptides
ATE361318T1 (de)	2000-05-12	2007-05-15	Amgen Inc	Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1294769B1 (de) *	2000-06-16	2011-01-05	Human Genome Sciences, Inc.	Immunspezifisch bindende antikörper gegen blys
WO2002016411A2 (en)	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EA010594B1 (ru)	2001-05-24	2008-10-30	Займодженетикс, Инк.	Слитые белки taci-иммуноглобулина
CA2446734A1 (en)	2001-05-24	2002-11-28	Human Genome Sciences, Inc.	Antibodies against tumor necrosis factor delta (april)
CA2453995A1 (en) *	2001-08-03	2003-02-20	Genentech, Inc.	Tacis and br3 polypeptides and uses thereof
US7494646B2 (en)	2001-09-06	2009-02-24	Agensys, Inc.	Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1516054B1 (de) *	2002-02-10	2009-12-02	Topotarget Switzerland SA	Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
WO2003072713A2 (en) *	2002-02-21	2003-09-04	Biogen Idec Ma Inc.	Use of bcma as an immunoregulatory agent
CN1692127A (zh) *	2002-07-25	2005-11-02	健泰科生物技术公司	Taci抗体及其用途
CA2520097C (en)	2003-03-28	2014-10-07	Biogen Idec Ma Inc.	Truncated baff receptors
ES2538469T3 (es) *	2003-06-05	2015-06-22	Genentech, Inc.	Terapia de combinación para trastornos de células B
US20050163775A1 (en) *	2003-06-05	2005-07-28	Genentech, Inc.	Combination therapy for B cell disorders
RU2006117324A (ru)	2003-10-20	2007-12-10	Байоджен Айдек Ма Инк. (Us)	Терапевтические режимы для антагонистов baff
PL1742966T3 (pl)	2004-04-22	2014-04-30	Agensys Inc	Przeciwciała i pochodzące z nich cząsteczki, które wiążą się z białkami STEAP-1
CN1786016B (zh) *	2004-12-09	2010-12-29	中国人民解放军军事医学科学院基础医学研究所	一种人工构建的生物活性分子及其制备方法
CA2590461A1 (en)	2004-12-23	2006-06-29	Laboratoires Serono S.A.	Bcma polypeptides and uses thereof
DE602006007323D1 (de) *	2005-01-28	2009-07-30	Biogen Idec Inc	VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
EP1922080A2 (de)	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
CA2618763A1 (en)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
EA015860B1 (ru)	2005-10-13	2011-12-30	Хьюман Дженом Сайенсиз, Инк.	Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
ES2618543T3 (es)	2005-11-23	2017-06-21	Genentech, Inc.	Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
WO2007134326A2 (en)	2006-05-15	2007-11-22	Ares Trading S.A.	Methods for treating autoimmune diseases using a taci-ig fusion molecule
DK2061814T3 (da)	2006-10-27	2012-08-27	Genentech Inc	Antistoffer og immunokonjugater og anvendelse deraf.
MD24Z (ro) *	2008-12-02	2010-01-31	Василе ЖОВМИР	Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) *	2008-12-02	2010-01-31	Василе ЖОВМИР	Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) *	2008-12-02	2010-01-31	Василе ЖОВМИР	Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) *	2008-12-02	2010-01-31	Василе ЖОВМИР	Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
EP2488200A4 (de) *	2009-10-14	2013-06-12	Merck Sharp & Dohme	April-antagonisten und verfahren zu ihrer verwendung
UA112434C2 (uk)	2011-05-27	2016-09-12	Ґлаксо Ґруп Лімітед	Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013171296A1 (en)	2012-05-16	2013-11-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Diagnostic and treatment of sarcoidosis
TW201425336A (zh) *	2012-12-07	2014-07-01	Amgen Inc	Ｂｃｍａ抗原結合蛋白質
EP2762497A1 (de)	2013-02-05	2014-08-06	EngMab AG	Bispezifische Antikörper gegen CD3-epsilon und BCMA
CN104968682A (zh)	2013-02-05	2015-10-07	英格玛布股份公司	针对CD3ε和BCMA的双特异性抗体
EP2762496A1 (de)	2013-02-05	2014-08-06	EngMab AG	Verfahren zur Auswahl von Antikörpern gegen BCMA
US9688767B2 (en)	2013-03-15	2017-06-27	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
NL2011406C2 (en)	2013-09-06	2015-03-10	Bionovion Holding B V	Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
GB201317929D0 (en) *	2013-10-10	2013-11-27	Ucl Business Plc	Chimeric antigen receptor
ES2703549T3 (es) *	2013-11-19	2019-03-11	Regeneron Pharma	Animales no humanos que tienen un gen de un ligando inductor de la proliferación humanizado
US20170247462A1 (en)	2014-07-03	2017-08-31	Oklahoma Medical Research Foundation	Treatment of multiple sclerosis and neuromyelitis optica
EP2982692A1 (de)	2014-08-04	2016-02-10	EngMab AG	Bispezifische Antikörper gegen CD3-Epsilon und BCMA
EP3023437A1 (de)	2014-11-20	2016-05-25	EngMab AG	Bispezifische Antikörper gegen CD3epsilon und BCMA
EP3029068A1 (de)	2014-12-03	2016-06-08	EngMab AG	Bispezifische Antikörper gegen CD3-Epsilon-BCMA und zur Verwendung bei der Behandlung von Krankheiten
NL2014108B1 (en)	2015-01-09	2016-09-30	Aduro Biotech Holdings Europe B V	Altered april binding antibodies.
HUE048939T2 (hu)	2015-08-03	2020-09-28	Engmab Sarl	Human B sejt érési antigén elleni monoklonális antitestek (BCMA)
TWI811023B (zh)	2015-08-17	2023-08-01	美商健生生物科技公司	抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
WO2017083511A1 (en) *	2015-11-13	2017-05-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-bcma polypeptides and proteins
CN118420760A (zh)	2015-11-25	2024-08-02	威特拉公司	April的抗体分子及其应用
MX2018009700A (es)	2016-02-17	2019-01-24	Seattle Genetics Inc	Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
EP3471773A4 (de)	2016-06-21	2020-07-08	Teneobio, Inc.	Cd3-bindende antikörper
EP4050034B1 (de)	2016-09-14	2024-05-08	TeneoOne, Inc.	Cd3-bindende antikörper
KR102687833B1 (ko)	2016-11-02	2024-07-24	브리스톨-마이어스 스큅 컴퍼니	다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
IL317134A (en)	2016-12-21	2025-01-01	Teneobio Inc	An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
WO2018184966A1 (en)	2017-04-03	2018-10-11	F. Hoffmann-La Roche Ag	Antibodies binding to steap-1
US11427642B2 (en)	2017-06-20	2022-08-30	Teneoone, Inc.	Anti-BCMA heavy chain-only antibodies
SG11201912774RA (en)	2017-06-20	2020-01-30	Teneobio Inc	Anti-bcma heavy chain-only antibodies
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
MA52640A (fr)	2018-05-16	2021-03-24	Janssen Biotech Inc	Procédés de traitement de cancers et d'amélioration de l'efficacité d'agents thérapeutiques de redirection de lymphocytes t
MY199538A (en)	2018-06-01	2023-11-06	Novartis Ag	Binding molecules against bcma and uses thereof
JP7554742B2 (ja)	2018-07-03	2024-09-20	マレンゴ・セラピューティクス，インコーポレーテッド	抗ｔｃｒ抗体分子およびその使用
WO2020018922A1 (en)	2018-07-20	2020-01-23	Teneobio, Inc.	Heavy chain antibodies binding to cd19
US12180298B2 (en)	2019-04-05	2024-12-31	Teneobio, Inc.	Heavy chain antibodies binding to PSMA
KR20220010544A (ko)	2019-05-21	2022-01-25	노파르티스 아게	Cd19 결합 분자 및 이의 용도
EA202290054A1 (ru)	2019-06-14	2022-03-25	Тенеобио, Инк.	Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
KR20220068984A (ko)	2019-07-30	2022-05-26	상하이 한서 바이오메디컬 컴퍼니 리미티드	항-bcma 항체, 이의 항원-결합 단편 및 이의 의학적 용도
KR20230005179A (ko)	2020-04-29	2023-01-09	테네오바이오, 인코포레이티드	변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
TWI838621B (zh)	2020-04-29	2024-04-11	美商泰尼歐萬公司	具有經修飾重鏈恆定區之多特異性重鏈抗體
PH12022553023A1 (en)	2020-05-11	2024-03-04	Janssen Biotech Inc	Methods for treating multiple myeloma
AU2021279035A1 (en) *	2020-05-29	2023-02-02	Aduro Biotech Holding, Europe B.V.	Methods of treating IgA nephropathy with an APRIL binding antibody
AU2021300179A1 (en)	2020-06-30	2023-02-02	Teneobio, Inc.	Multi-specific antibodies binding to BCMA
IL305144A (en)	2021-02-16	2023-10-01	Janssen Pharmaceutica Nv	Trispecific antibodies targeting BCMA, GPRC5D and CD3
US20250099579A1 (en)	2021-04-08	2025-03-27	Marengo Therapeutics, Inc.	Multispecific molecules binding to tcr and uses thereof
TW202309522A (zh)	2021-05-11	2023-03-01	美商健生生物科技公司	用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
CA3228678A1 (en)	2021-08-11	2023-02-16	Amato J. Giaccia	Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
IL312503A (en)	2021-11-03	2024-07-01	Janssen Biotech Inc	Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
US12173081B2 (en)	2023-03-21	2024-12-24	Biograph 55, Inc.	CD19/CD38 multispecific antibodies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en)	1988-12-20	1993-01-05	Baylor College Of Medicine	Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en)	1989-06-05	1993-10-26	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides
US5264564A (en)	1989-10-24	1993-11-23	Gilead Sciences	Oligonucleotide analogs with novel linkages
US6218510B1 (en) *	1994-03-02	2001-04-17	Brigham & Woman's Hospital	B7-1 and B7-2 polypeptides
PT897390E (pt)	1996-03-14	2004-03-31	Human Genome Sciences Inc	Factor delta e epsilon de necrose tumoral humana
US6541224B2 (en)	1996-03-14	2003-04-01	Human Genome Sciences, Inc.	Tumor necrosis factor delta polypeptides
ES2248823T5 (es)	1996-10-25	2011-11-03	Human Genome Sciences, Inc.	Neutroquina alfa.
AU5705898A (en)	1996-12-17	1998-07-15	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
WO1998055620A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
IL133316A0 (en)	1997-06-06	2001-04-30	Regeneron Pharma	Ntn-2 member of tnf ligand family
AU9376498A (en)	1997-09-05	1999-03-22	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
SK3542000A3 (en) *	1997-09-12	2000-08-14	Apotech R & D Sa	Nucleic acid coding ligand april, a vector, a host cell, method for preparing ligand april, a polypeptide of ligand april, a pharmaceutical composition and an antibody, and use thereof
BR9812433A (pt)	1997-09-12	2000-09-26	Biogen Inc	Kay- uma proteìna do sistema de imunização
US6297367B1 (en)	1997-12-30	2001-10-02	Chiron Corporation	Polynucleotide encoding TNFL1
AU2093499A (en)	1997-12-30	1999-07-19	Chiron Corporation	Members of tnf and tnfr families
AU1467000A (en)	1998-11-04	2000-05-22	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en)	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
NZ512753A (en) *	1999-01-07	2003-10-31	Zymogenetics Inc	Soluble receptor BR43x2 related proteins useful for inhibiting ztnf4
US20060067933A1 (en)	1999-01-07	2006-03-30	Gross Jane A	Soluble receptor BR43x2 and methods of using
TR200102147T2 (tr)	1999-01-25	2002-04-22	Biogen, Inc.	BAFF, ilişkili bloke edici maddeler ve bunların bağışıklık karşılığında B-hücreleri ve imünoglobülinlerin uyarımı ve engellenmesinde kullanımları
US6475986B1 (en)	1999-02-02	2002-11-05	Research Development Foundation	Uses of THANK, a TNF homologue that activates apoptosis
EP1157110A4 (de)	1999-02-23	2006-05-10	Human Genome Sciences Inc	Neutrokin-alpha und Neutrokin-alpha Spleissvarianten
JP2002541779A (ja) *	1999-02-24	2002-12-10	ザジュネラルホスピタルコーポレーション	シグナル伝達中間体のクローニング方法
AU3633000A (en)	1999-03-26	2000-10-16	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
US6475987B1 (en)	1999-05-06	2002-11-05	National Jewish Medical And Research Center	Tall-1 receptor homologues
WO2001012812A2 (en)	1999-08-17	2001-02-22	Biogen, Inc.	Baff receptor (bcma), an immunoregulatory agent
CA2897626C (en)	2000-02-11	2020-03-24	Biogen Idec Ma Inc.	Heterologous polypeptide of the tnf family
AU2048501A (en) *	2000-02-16	2001-08-27	Genentech Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040013674A1 (en)	2001-04-27	2004-01-22	Christine Ambrose	Taci as an anti-tumor agent
ATE361318T1 (de)	2000-05-12	2007-05-15	Amgen Inc	Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
EP1294769B1 (de)	2000-06-16	2011-01-05	Human Genome Sciences, Inc.	Immunspezifisch bindende antikörper gegen blys
AU2001288260A1 (en)	2000-08-15	2002-03-13	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1456347A4 (de)	2001-11-16	2006-08-02	Human Genome Sciences Inc	Immunspezifisch an blys bindende antikörper

2000
- 2000-05-10 UA UA2002053779A patent/UA74798C2/uk unknown
- 2000-10-05 EE EEP200200181A patent/EE05212B1/xx not_active IP Right Cessation
- 2000-10-05 EP EP07106184A patent/EP1847273A1/de not_active Withdrawn
- 2000-10-05 DE DE60034586T patent/DE60034586T2/de not_active Expired - Lifetime
- 2000-10-05 EP EP10181119.8A patent/EP2324844A3/de not_active Withdrawn
- 2000-10-05 SK SK451-2002A patent/SK286331B6/sk not_active IP Right Cessation
- 2000-10-05 TR TR2002/00912T patent/TR200200912T2/xx unknown
- 2000-10-05 GE GE4770A patent/GEP20043375B/en unknown
- 2000-10-05 EP EP00968780A patent/EP1223964B1/de not_active Revoked
- 2000-10-05 CZ CZ20021169A patent/CZ297633B6/cs not_active IP Right Cessation
- 2000-10-05 IL IL14883900A patent/IL148839A0/xx unknown
- 2000-10-05 WO PCT/US2000/027579 patent/WO2001024811A1/en active Application Filing
- 2000-10-05 CN CNB008162557A patent/CN1263507C/zh not_active Expired - Fee Related
- 2000-10-05 CA CA2386463A patent/CA2386463C/en not_active Expired - Fee Related
- 2000-10-05 PL PL355102A patent/PL204010B1/pl unknown
- 2000-10-05 MX MXPA02003393A patent/MXPA02003393A/es active IP Right Grant
- 2000-10-05 KR KR1020027004434A patent/KR100759295B1/ko not_active Expired - Fee Related
- 2000-10-05 EA EA200200427A patent/EA005601B1/ru unknown
- 2000-10-05 AU AU78645/00A patent/AU776852B2/en not_active Ceased
- 2000-10-05 JP JP2001527810A patent/JP4880155B2/ja not_active Expired - Fee Related
- 2000-10-05 RS YU25302A patent/RS51602B/sr unknown
- 2000-10-05 DK DK00968780T patent/DK1223964T3/da active
- 2000-10-05 AT AT00968780T patent/ATE360434T1/de active
- 2000-10-05 HU HU0203567A patent/HUP0203567A2/hu unknown
- 2000-10-05 BR BR0014583-1A patent/BR0014583A/pt not_active Application Discontinuation
- 2000-10-05 NZ NZ517907A patent/NZ517907A/en not_active IP Right Cessation
2002
- 2002-03-21 IL IL148839A patent/IL148839A/en not_active IP Right Cessation
- 2002-03-22 IS IS6322A patent/IS6322A/is unknown
- 2002-04-02 US US10/115,192 patent/US7276241B2/en not_active Expired - Fee Related
- 2002-04-02 ZA ZA200202578A patent/ZA200202578B/xx unknown
- 2002-04-04 NO NO20021594A patent/NO331683B1/no not_active IP Right Cessation
- 2002-04-30 BG BG106670A patent/BG65473B1/bg unknown
- 2002-08-14 HK HK02105960.3A patent/HK1044710B/zh not_active IP Right Cessation
2010
- 2010-03-10 IL IL204401A patent/IL204401A/en not_active IP Right Cessation
2011
- 2011-01-07 JP JP2011002461A patent/JP2011079863A/ja active Pending

Also Published As

Publication number	Publication date
IL204401A (en)	2014-12-31
NO20021594D0 (no)	2002-04-04
KR20020053066A (ko)	2002-07-04
AU7864500A (en)	2001-05-10
NZ517907A (en)	2004-01-30
IL148839A0 (en)	2002-09-12
EA005601B1 (ru)	2005-04-28
TR200200912T2 (tr)	2002-07-22
UA74798C2 (uk)	2006-02-15
PL355102A1 (en)	2004-04-05
CA2386463C (en)	2012-02-07
AU776852B2 (en)	2004-09-23
CZ297633B6 (cs)	2007-02-14
BG106670A (en)	2002-12-29
EP2324844A2 (de)	2011-05-25
CN1399556A (zh)	2003-02-26
US20030082175A1 (en)	2003-05-01
RS51602B (sr)	2011-08-31
SK286331B6 (en)	2008-07-07
DE60034586T2 (de)	2008-02-28
EP1847273A1 (de)	2007-10-24
KR100759295B1 (ko)	2007-09-18
YU25302A (sh)	2005-06-10
EA200200427A1 (ru)	2002-12-26
GEP20043375B (en)	2004-11-25
EP1223964A1 (de)	2002-07-24
CA2386463A1 (en)	2001-04-12
SK4512002A3 (en)	2002-12-03
JP2003510366A (ja)	2003-03-18
JP2011079863A (ja)	2011-04-21
EP1223964B1 (de)	2007-04-25
BR0014583A (pt)	2002-06-11
HK1044710A1 (en)	2002-11-01
US7276241B2 (en)	2007-10-02
NO331683B1 (no)	2012-02-20
ZA200202578B (en)	2003-07-02
ATE360434T1 (de)	2007-05-15
NO20021594L (no)	2002-06-05
IS6322A (is)	2002-03-22
CN1263507C (zh)	2006-07-12
HK1044710B (zh)	2007-12-07
IL148839A (en)	2015-01-29
DK1223964T3 (da)	2007-08-27
WO2001024811A1 (en)	2001-04-12
EP2324844A3 (de)	2013-12-11
EE05212B1 (et)	2009-10-15
MXPA02003393A (es)	2004-08-19
JP4880155B2 (ja)	2012-02-22
CZ20021169A3 (cs)	2002-09-11
EE200200181A (et)	2003-06-16
BG65473B1 (bg)	2008-09-30
HUP0203567A2 (hu)	2003-02-28
PL204010B1 (pl)	2009-12-31

Publication	Publication Date	Title
ATE360434T1 (de)	2007-05-15	April rezeptor (bcma) und verwendungen davon
SK500172015A3 (de)	2002-07-02
EP1151002A4 (de)	2002-05-02	Antikörper spezifisch für kdr und ihre verwendungen
CY2015018I2 (el)	2016-04-13	Ανθρωπινα αντισωματα ειδικα για kdr και χρησεις αυτων
DE60042066D1 (de)	2009-06-04	Chimärische dr4 antikörper und ihre verwendung
DE60129572D1 (de)	2007-09-06	Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
FR2789386B1 (fr)	2001-08-03	Composition ceramique piezoelectrique et dispositif ceramique piezoelectrique l'utilisant
ATA192799A (de)	2001-10-15	Neue verwendung von antikörpern als impfstoffe
FI960744A0 (fi)	1996-02-19	Sekoitin kahden virtaavan väliaineen sekoittamiseksi keskenään

Legal Events

Date	Code	Title	Description
2008-04-17	8363	Opposition against the patent